Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration - Wikidata - wikimedia - TriplyDB

Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration

Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration

http://www.wikidata.org/entity/Q28210465

about

sameAs

Lipoxins: nature's way to resolve inflammation Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs Lipoxin A4 inhibits immune cell binding to salivary epithelium and vascular endothelium.Endogenous pro-resolving and anti-inflammatory lipid mediators: a new pharmacologic genus.Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators.Systems approach with inflammatory exudates uncovers novel anti-inflammatory and pro-resolving mediators.Specialized pro-resolving lipid mediators in the inflammatory response: An update Host control of Mycobacterium tuberculosis is regulated by 5-lipoxygenase-dependent lipoxin production.Resolution, the grail for healthy ocular inflammation.Efficacy and safety of 15(R/S)-methyl-lipoxin A(4) in topical treatment of infantile eczema.MicroRNAs in resolution of acute inflammation: identification of novel resolvin D1-miRNA circuits.Mechanisms for anti-inflammatory effects of 1-[15(S)-hydroxyeicosapentaenoyl] lysophosphatidylcholine, administered intraperitoneally, in zymosan A-induced peritonitis Vagal nerve stimulation in prevention and management of coronary heart disease Novel anti-inflammatory--pro-resolving mediators and their receptors Macrophage Polarization during Murine Lyme Borreliosis.Chronic inflammation: a failure of resolution?Lipoxin A4 Preconditioning Attenuates Intestinal Ischemia Reperfusion Injury through Keap1/Nrf2 Pathway in a Lipoxin A4 Receptor Independent Manner Anti-inflammatory and proresolving lipid mediators.Mechanisms mediating reduced responsiveness of neonatal neutrophils to lipoxin A4.Lipoxins: resolutionary road.Paradigm shift in the pharmacological management of periodontal diseases.Eicosanoids and their drugs in cardiovascular diseases: focus on atherosclerosis and stroke.Natural resolution of inflammation.Bioactive lipids in pathological retinopathy.Recent Progress in Therapeutics for Inflammation-Associated Preterm Birth: A Review.Omega-3 fatty acids as an adjunct for periodontal therapy-a review.Special pro-resolving mediator (SPM) actions in regulating gastro-intestinal inflammation and gut mucosal immune responses.Aspirin-triggered lipoxin enhances macrophage phagocytosis of bacteria while inhibiting inflammatory cytokine production.Oral administration of 2-docosahexaenoyl lysophosphatidylcholine displayed anti-inflammatory effects on zymosan A-induced peritonitis.Activation of autophagy in macrophages by pro-resolving lipid mediators.Anti-inflammatory and pro-resolving properties of benzo-lipoxin A(4) analogs.Protective effects of n-6 fatty acids-enriched diet on intestinal ischaemia/reperfusion injury involve lipoxin A4 and its receptor.Inflammation-dependent alpha 5 beta 1 (very late antigen-5) expression on leukocytes reveals a functional role for this integrin in acute peritonitis.Lipoxin A4 ameliorates ischemia/reperfusion induced spinal cord injury in rabbit model.Immune modulation in gastrointestinal disorders: new opportunities for therapeutic peptides?Therapeutic effect of Lipoxin A4 in malaria-induced acute lung injury.Aspirin and (or) omega-3 polyunsaturated fatty acids protect against corticohippocampal neurodegeneration and downregulate lipoxin A4 production and formyl peptide receptor-like 1 expression in pentylenetetrazole-kindled rats.Analysis of the inflammatory response in HY-TCR transgenic mice highlights the pathogenic potential of CD4- CD8- T cells.Therapeutic Potential of Annexin A1 in Ischemia Reperfusion Injury.

P2860

Q26784376-9B8A6062-8088-4F72-B5E4-F471F10D466E Q27014988-6D812361-93E6-4D3D-B7AD-D8F7C026B12A Q30513559-7A142A8E-DDCA-4EF9-AE9C-358CB63CA1D8 Q31134484-9046E595-CE89-4335-A97E-AC618A0164A3 Q33356900-3C888963-5025-49C2-A694-D977F01D4DE5 Q33384350-F5E1447B-586C-4C94-A106-B703A8B130FA Q33657562-E073AC20-42B1-40BD-B70D-B8FFD1C43963 Q33831917-054828E9-2440-46D8-AA6B-6E7DD1FCABBE Q34126362-BE2AA061-C134-4D13-84D8-3920A106A68A Q34290400-8B8B289D-34BC-4AE4-AE83-68D4ACDB5F8A Q34502699-FB4C40D2-3F8D-45BA-ACE6-0EA7B0C70871 Q34636261-A1069E41-B6E7-4BA5-8396-2F40600AC781 Q34863015-F483218A-F5DA-4264-A396-AE9330B0E67C Q34982051-FC0C0DAC-55FC-4A0C-846B-7B7E173803A7 Q35745605-8B5065CD-FD34-45D1-90F3-A04F43EAB42C Q36780168-BCBA8AD8-976B-446C-A6DD-409C948BC060 Q37023439-CCC11F90-D215-47C8-9A42-F217E5B99026 Q37071968-2613B2ED-30EB-4244-9225-6DE6520DFE21 Q37117970-B282A482-A8C5-419F-9563-1727BD0B7254 Q37604436-A01DE3CF-3C16-41D7-B5E8-930907907D1B Q37964882-1C955EFF-6BB3-45D4-AD70-74DAAE50B393 Q37995534-DA6D9D92-658B-45F3-83C0-6D5A1011012F Q38127782-872ABA10-494C-4577-AA78-B10944AEC8F0 Q38159735-76EC79EB-50E4-482E-B51A-D72F3B3941BD Q38655581-73CABBDA-2FE6-4E02-A9A1-F6B122EF67C5 Q38736964-E6C31A3C-7C29-46D5-AE71-9685B8F8AFC6 Q39148416-7A68EB29-170E-4A05-8077-F11955BF7C73 Q39527391-F3138AA1-0D6C-4026-8C69-530DD8857AFA Q39701697-2B2E1EDB-6683-4F1E-A94C-0BA80799DB8B Q39961845-18EA9583-F727-4183-89BE-260488E9E4D8 Q42942697-E0455F18-28EB-4776-9606-63CAA04D1398 Q43114230-C534CC08-E6C1-4B2B-BC33-FE4832FE02B7 Q43185230-1477CBCE-8F7F-41CB-8D52-E28CD05B54DD Q43210142-73727530-BFE7-4611-AD5E-1BFFB6D78A15 Q43981293-CBD1BA1E-C2E8-48A7-B147-193ABAC76920 Q48022386-004E3D04-958F-4F92-952E-22C5251A671D Q48369250-0A4A73F2-5016-4530-8989-DF8770397A44 Q51573067-5802096D-01C3-4F38-BEE0-59B48E382BA2 Q54988971-B5B78ED1-021F-47F9-933F-2838F47F6B05

P2860

Lipoxins and novel 15-epi-lipoxin analogs display potent anti-inflammatory actions after oral administration

http://www.wikidata.org/entity/Q28210465

description

2004 nî lūn-bûn

@nan

2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Lipoxins and novel 15-epi-lipo ...... ions after oral administration

@ast

Lipoxins and novel 15-epi-lipo ...... ions after oral administration

@en

Lipoxins and novel 15-epi-lipo ...... ions after oral administration

@nl

type

label

Lipoxins and novel 15-epi-lipo ...... ions after oral administration

@ast

Lipoxins and novel 15-epi-lipo ...... ions after oral administration

@en

Lipoxins and novel 15-epi-lipo ...... ions after oral administration

@nl

prefLabel

Lipoxins and novel 15-epi-lipo ...... ions after oral administration

@ast

Lipoxins and novel 15-epi-lipo ...... ions after oral administration

@en

Lipoxins and novel 15-epi-lipo ...... ions after oral administration

@nl

P1433

Q28210465-F18375DC-D62C-442B-8D59-6D52C4381DAB

P1476

Q28210465-53FD965C-1B89-44D3-AE51-23926CF89648

P2093

Q28210465-09767476-772B-4C1D-B9C9-74911C6C4869

Q28210465-6D153AAE-3D6D-4736-89F3-C0EFAFF07EE0

Q28210465-734BF396-DEEF-4898-BE4E-FF1AFDCFC356

Q28210465-8ADF3573-3F03-4E7E-BFD1-174269D3C877

Q28210465-9A400B9A-D29A-4070-BCF9-FAD661F20F79

Q28210465-9D75A935-3D3A-4C25-9FD5-DCFC7701F868

Q28210465-CD95CEF2-A93A-4739-B2E9-001C3F540BAA

Q28210465-DE359058-BC52-40E9-9758-9E290D17DB71

Q28210465-E3EDE8EE-AF75-4811-8E18-73938F47A098

Q28210465-F44DE006-CA8B-4CFF-96CB-C5F934E71C90

P2860

Q28210465-02EA90F8-895D-4171-A4A7-D3670A233D80

Q28210465-041FFD35-7ED9-492E-B9D9-EF0AD6655241

Q28210465-39D4AB22-1048-4C60-981D-C0FBBD4F1A2A

Q28210465-3E0D2029-AE4B-4A9D-BF1F-98FB185E5789

Q28210465-3E5C4C68-86CF-4AF1-8CCC-2BDD5B98297F

Q28210465-531C7C9F-2F2A-4B27-BF63-893A8E7E7A12

Q28210465-56EB9319-AABF-4CDD-8A1F-105A1267871D

Q28210465-5CB5CF5A-CAC3-4D2E-8353-7F5E7A75B15A

Q28210465-5D58BF7A-FF98-4336-9F4E-0751B75C285D

Q28210465-6A315F97-BEDE-439E-964B-E177DC3C716F

P304

Q28210465-FC1867E2-D5D5-45B6-AABB-F1848C1F408E

P31

Q28210465-20C341B6-EDB1-4854-AC36-EF08BFCECF64

P3181

Q28210465-352F7382-EEFE-487A-98A8-F414830D9150

P356

Q28210465-B7D4FE7D-70DE-43C5-AE56-3F53AF0F391B

P407

Q28210465-9938FF43-CE3E-4395-AC11-848B9012DE46

P433

Q28210465-536B4F91-7EC4-430B-831D-172C1D753773

P478

Q28210465-320CECA9-5DDC-461E-9A57-43AC8CA8DF8A

P50

Q28210465-CC12EF18-1DBD-4D04-9542-6A1D80782BED

P577

Q28210465-AF4EABBA-1784-43C6-A4DD-4C711AD1E8CC

P5875

Q28210465-E242A394-389B-4FB8-A37B-41F0EF9282D7

P698

Q28210465-412C49A9-5D27-4BAC-9EAB-465197FD7CD7

P921

Q28210465-98BB4D5F-D087-4A68-A72B-88F2B394D1EF

P932

Q28210465-C1FBCA88-E98A-44FB-9240-5CFA523876AA

P3181

P356

P1433

British Journal of Pharmacology

P1476

Lipoxins and novel 15-epi-lipo ...... ions after oral administration

@en

P2093

Babu Subramanyam

http://www.w3.org/2001/XMLSchema#string

Birgitta A Schmidt

http://www.w3.org/2001/XMLSchema#string

Charles N Serhan

http://www.w3.org/2001/XMLSchema#string

H Daniel Perez

http://www.w3.org/2001/XMLSchema#string

John F Parkinson

http://www.w3.org/2001/XMLSchema#string

John G Bauman

http://www.w3.org/2001/XMLSchema#string

Karsten Gronert

http://www.w3.org/2001/XMLSchema#string

Pallavi R Devchand

http://www.w3.org/2001/XMLSchema#string

Rose-Laure Moussignac

http://www.w3.org/2001/XMLSchema#string

William J Guilford

http://www.w3.org/2001/XMLSchema#string

P2860

Lipoxin A4 stable analogs are potent mimetics that stimulate human monocytes and THP-1 cells via a G-protein-linked lipoxin A4 receptor

Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions

Aspirin-triggered 15-epi-lipoxin A4 (LXA4) and LXA4 stable analogues are potent inhibitors of acute inflammation: evidence for anti-inflammatory receptors

Interaction of a selective cyclooxygenase-2 inhibitor with aspirin and NO-releasing aspirin in the human gastric mucosa

Lipoxins and aspirin-triggered 15-epi-lipoxins are endogenous components of antiinflammation: emergence of the counterregulatory side

Unorthodox routes to prostanoid formation: new twists in cyclooxygenase-initiated pathways

Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor

An aspirin-triggered lipoxin A4 stable analog displays a unique topical anti-inflammatory profile

Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo

Leukotriene B4 receptor transgenic mice reveal novel protective roles for lipoxins and aspirin-triggered lipoxins in reperfusion

P304

43-52

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

999906

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/SJ.BJP.0705912

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

143

http://www.w3.org/2001/XMLSchema#string

P50

Gerard Bannenberg

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8407817

http://www.w3.org/2001/XMLSchema#string

P698

15302682

http://www.w3.org/2001/XMLSchema#string

P921

P932

1575273

http://www.w3.org/2001/XMLSchema#string